Results 221 to 230 of about 692,682 (292)

Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro. [PDF]

Methods Protoc, 2023
Garige M, Ghosh S, Roelofs B, Rao VA, Sourbier C.   +4 more
europepmc   +1 more source

Immunogenicity, Safety and Efficacy Comparison of Wockhardt’s Biosimilar Insulin Glargine—Glaritus® with Reference Product— Lantus®: Study Protocol & Early Data Trends

, 2018
Surendra Kumar Sharma, Ajay Ajmani, Pooja Khosla, Pradip Mukhopadhyay, Girish Bhatia, K. G. Prakash, Gaurav Chhaya, Pravin Dinkar Supe, Vini Pavithran, H. Bora, Rajeev Jain, Shahu Ingole, Agam Shah   +12 more
openalex   +2 more sources

The risk of cancer among insulin glargine users in Lithuania: A retrospective population-based study. [PDF]

Open Med (Wars)
Jonusas J, Drevinskaitė M, Linkeviciute-Ulinskiene D, Ladukas A, Patašius A, Zabulienė L, Smailytė G.   +6 more
europepmc   +1 more source

Management of diabetic ketoacidosis in children: Does early insulin glargine help improve outcomes? [PDF]

J Diabetes
Ohman-Hanson R, Alonso GT, Pyle L, McDonough R, Clements M.   +4 more
europepmc   +1 more source

Effectiveness and Safety of Insulin Glargine 300 U/ml in High-Risk Subgroups (Renal Impairment and Older Age ≥ 70 years) of Insulin-Naïve People with Type 2 Diabetes: A Post hoc Analysis of Real-World ATOS Study. [PDF]

Diabetes Ther
Tirosh A, Khan N, Vargas-Uricoechea H, Galstyan G, Al Shaikh AR, Makkar BM, Mabunay MA, Melas-Melt L, Pilorget V, Karalliedde J.   +9 more
europepmc   +1 more source

Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β ‐cell protection in individuals with type 2 diabetes

, 2010
Thomas Först, Martin Larbig, C Hohberg, S Först, Stephan Diessel, Margret Borchert, W. Roth, A Pfützner   +7 more
openalex   +2 more sources

Pharmacokinetics, Pharmacodynamics, and Bioequivalence of Test Insulin Glargine Versus Reference Preparation (Lantus^®) in Healthy Male Volunteers-By Euglycemic Clamp Technique. [PDF]

Pharmaceutics
Li Z, Liu M, Tao Y, Wan L, Chen Y, Zhu M, Zhao H, Tang C.   +7 more
europepmc   +1 more source

Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study [PDF]

, 2018
Thomas Blevins, Abhijit Barve, Bin Sun, Yaron Raiter, Patrick Aubonnet, Rafael Muniz, Sandeep N. Athalye, Michael Ankersen   +7 more
openalex   +1 more source

Prescription Dispensing for Insulin Glargine After Interchangeable Biosimilar Designation.

JAMA Health Forum
Murphy SJ, Holtkamp NC.
europepmc   +1 more source

Comparative effectiveness of insulin glargine, glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in veterans with type 2 diabetes. [PDF]

Diabetes Obes Metab
Shen J, Sarwal A, Singh R, Hartsell SE, Wei G, Nevers M, Christensen JC, Takyi A, Katkam N, Derington CG, Deshmukh VG, Boucher RE, Drakos SG, Greene T, Beddhu S.   +14 more
europepmc   +1 more source